PMV Pharmaceuticals (PMVP) Free Cash Flow (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Free Cash Flow came in at -$19.7 million in Q1 2026, down 7.71% YoY from -$21.3 million in Q1 2025, and down 14.39% on a QoQ basis from -$17.2 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Free Cash Flow (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Free Cash Flow data on file, last reported at -$19.7 million in Q1 2026.
- Quarterly Free Cash Flow fell 7.71% year-over-year to -$19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$75.0 million (down 40.4% YoY) and the FY2025 annual result came in at -$73.6 million, down 41.72% from the prior year.
- Free Cash Flow declined to -$19.7 million in Q1 2026, from -$17.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.6 million in Q2 2024 to a low of -$21.6 million in Q3 2022.
- A 5-year average of -$15.6 million and a median of -$16.8 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow surged 88.1% — and 2025, when it sank 1043.13%.
- Tracing PMVP's Free Cash Flow over 5 years: stood at -$9.2 million in 2022, then declined by 23.46% to -$11.3 million in 2023, then plunged by 47.6% to -$16.7 million in 2024, then decreased by 2.91% to -$17.2 million in 2025, then dropped by 14.39% to -$19.7 million in 2026.
- The last three Free Cash Flow figures came in at -$19.7 million (Q1 2026), -$17.2 million (Q4 2025), and -$19.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | -14.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.68 Mn |
| Mar 31, 2026 | -19.68 Mn |
| Dec 31, 2025 | -17.20 Mn |
| Dec 31, 2025 | -17.20 Mn |
| Sep 30, 2025 | -19.82 Mn |
| Sep 30, 2025 | -19.82 Mn |
| Jun 30, 2025 | -18.31 Mn |
| Jun 30, 2025 | -18.31 Mn |
| Mar 31, 2025 | -18.27 Mn |
| Mar 31, 2025 | -18.27 Mn |
| Dec 31, 2024 | -16.72 Mn |
| Dec 31, 2024 | -16.72 Mn |
| Sep 30, 2024 | -16.84 Mn |
| Sep 30, 2024 | -16.84 Mn |
| Jun 30, 2024 | -1.60 Mn |
| Jun 30, 2024 | -1.60 Mn |
| Mar 31, 2024 | -16.78 Mn |
| Mar 31, 2024 | -16.78 Mn |
| Dec 31, 2023 | -11.33 Mn |
| Dec 31, 2023 | -11.33 Mn |